MX2022010157A - Receptores de células t restringidos a hla clase ii contra ras con mutación g12v. - Google Patents
Receptores de células t restringidos a hla clase ii contra ras con mutación g12v.Info
- Publication number
- MX2022010157A MX2022010157A MX2022010157A MX2022010157A MX2022010157A MX 2022010157 A MX2022010157 A MX 2022010157A MX 2022010157 A MX2022010157 A MX 2022010157A MX 2022010157 A MX2022010157 A MX 2022010157A MX 2022010157 A MX2022010157 A MX 2022010157A
- Authority
- MX
- Mexico
- Prior art keywords
- cell receptors
- mutation
- restricted
- hla class
- tcrs
- Prior art date
Links
- 108091008874 T cell receptors Proteins 0.000 title abstract 4
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 title abstract 4
- 230000035772 mutation Effects 0.000 title 1
- 241000124008 Mammalia Species 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 210000004027 cell Anatomy 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 230000000890 antigenic effect Effects 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 239000013604 expression vector Substances 0.000 abstract 1
- 210000000265 leukocyte Anatomy 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 238000003259 recombinant expression Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001111—Immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/82—Translation products from oncogenes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5748—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncogenic proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- Toxicology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Analytical Chemistry (AREA)
- Mycology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Plant Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
Abstract
Se describen receptores de células T aislados o purificados (TCR), en donde los TCR tienen especificidad antigénica para una secuencia de aminoácidos de RAS mutada presentada por una molécula clase II de antígeno leucocitario humano (HLA). También se proporcionan polipéptidos y proteínas relacionadas, así como ácidos nucleicos, vectores de expresión recombinante, células hospedadoras, poblaciones de células y composiciones farmacéuticas relacionadas. También se describen métodos para detectar la presencia de cáncer en un mamífero y métodos para tratar o prevenir el cáncer en un mamífero.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062981856P | 2020-02-26 | 2020-02-26 | |
| PCT/US2021/019775 WO2021173902A1 (en) | 2020-02-26 | 2021-02-26 | Hla class ii-restricted t cell receptors against ras with g12v mutation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022010157A true MX2022010157A (es) | 2022-10-18 |
Family
ID=74885105
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022010157A MX2022010157A (es) | 2020-02-26 | 2021-02-26 | Receptores de células t restringidos a hla clase ii contra ras con mutación g12v. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230159614A1 (es) |
| EP (1) | EP4110804A1 (es) |
| JP (1) | JP2023527613A (es) |
| KR (1) | KR20220143939A (es) |
| CN (1) | CN115244075A (es) |
| AU (1) | AU2021225872A1 (es) |
| BR (1) | BR112022016661A2 (es) |
| CA (1) | CA3169086A1 (es) |
| GB (1) | GB2610069A (es) |
| MX (1) | MX2022010157A (es) |
| TW (1) | TW202140537A (es) |
| WO (1) | WO2021173902A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2021389909A1 (en) * | 2020-11-24 | 2023-06-22 | Shanghai GenBase Biotechnology Co., Ltd. | Ras mutant epitope peptide and t cell receptor recognizing ras mutant |
| JP2024507929A (ja) | 2021-02-25 | 2024-02-21 | アラウノス セラピューティクス インコーポレイテッド | 多シストロン性発現カセットを含む組換えベクター及びそれらの使用方法 |
| JP2024518378A (ja) | 2021-05-05 | 2024-05-01 | イマティクス バイオテクノロジーズ ゲーエムベーハー | Ｐｒａｍｅに特異的に結合する抗原結合タンパク質 |
| WO2023150562A1 (en) | 2022-02-01 | 2023-08-10 | Alaunos Therapeutics, Inc. | Methods for activation and expansion of t cells |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003265948B8 (en) | 2002-09-06 | 2009-09-03 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Immunotherapy with in vitro-selected antigen-specific lymphocytes after nonmyeloablative lymphodepleting chemotherapy |
| US8383099B2 (en) | 2009-08-28 | 2013-02-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Adoptive cell therapy with young T cells |
| WO2012129201A1 (en) | 2011-03-22 | 2012-09-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of growing tumor infiltrating lymphocytes in gas-permeable containers |
| BR112020005469A2 (pt) * | 2017-09-20 | 2020-09-29 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | receptores de células t restritivas a hla classe ii contra ras mutado |
| AU2018378200A1 (en) * | 2017-12-04 | 2020-07-02 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | HLA class I-restricted T cell receptors against mutated RAS |
| GB201804724D0 (en) * | 2018-03-23 | 2018-05-09 | Univ Oslo Hf | Method of diagnosing cceliac disease |
| WO2019231326A1 (en) * | 2018-05-31 | 2019-12-05 | ACADEMISCH ZIEKENHUIS LEIDEN (h.o.d.n.LUMC) | Teipp neoantigens and uses thereof |
-
2021
- 2021-02-26 JP JP2022551537A patent/JP2023527613A/ja active Pending
- 2021-02-26 AU AU2021225872A patent/AU2021225872A1/en active Pending
- 2021-02-26 BR BR112022016661A patent/BR112022016661A2/pt unknown
- 2021-02-26 CA CA3169086A patent/CA3169086A1/en active Pending
- 2021-02-26 EP EP21712694.5A patent/EP4110804A1/en active Pending
- 2021-02-26 US US17/802,464 patent/US20230159614A1/en active Pending
- 2021-02-26 WO PCT/US2021/019775 patent/WO2021173902A1/en unknown
- 2021-02-26 GB GB2212195.8A patent/GB2610069A/en active Pending
- 2021-02-26 TW TW110106886A patent/TW202140537A/zh unknown
- 2021-02-26 KR KR1020227033222A patent/KR20220143939A/ko unknown
- 2021-02-26 CN CN202180016761.4A patent/CN115244075A/zh active Pending
- 2021-02-26 MX MX2022010157A patent/MX2022010157A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112022016661A2 (pt) | 2022-10-11 |
| TW202140537A (zh) | 2021-11-01 |
| AU2021225872A1 (en) | 2022-09-15 |
| WO2021173902A1 (en) | 2021-09-02 |
| JP2023527613A (ja) | 2023-06-30 |
| US20230159614A1 (en) | 2023-05-25 |
| CN115244075A (zh) | 2022-10-25 |
| EP4110804A1 (en) | 2023-01-04 |
| GB202212195D0 (en) | 2022-10-05 |
| GB2610069A (en) | 2023-02-22 |
| KR20220143939A (ko) | 2022-10-25 |
| CA3169086A1 (en) | 2021-09-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020005765A (es) | Receptores de celulas t restringidos a antigeno leucocitario humano (hla) clase i contra sarcoma de rata (ras) mutado. | |
| MX2022010157A (es) | Receptores de células t restringidos a hla clase ii contra ras con mutación g12v. | |
| MX2022009825A (es) | Receptores de células t restringidas por hla de la clase i contra ras con mutación g12v. | |
| MX2020003117A (es) | Receptores de celulas t restringidas a hla de clase ii contra ras mutado. | |
| MX2021015877A (es) | Receptores de celulas t que reconocen la mutacion r175h o y220c en p53. | |
| MX2022009654A (es) | Receptor de células t restringido por hla de la clase i contra ras con mutación g12d. | |
| CR20200170A (es) | Receptores de células t que reconocen p53 mutado | |
| MX2019009641A (es) | Receptores de la celula t que reconocen mhc de mage-a3 de clase ii-restringida. | |
| SA518391109B1 (ar) | Kras مستقبلات الخلايا التائية التي تميز hla-cw8 المطفرة المقيدة بـ | |
| EP3412680B1 (en) | Novel peptides that bind to types of mhc class ii and their use in diagnosis and treatment | |
| CA3066635A1 (en) | Neoantigen identification, manufacture, and use | |
| CA2848209C (en) | T cell receptors recognizing hla-a1- or hla-cw7-restricted mage | |
| US20220241331A1 (en) | Identification of recurrent mutated neopeptides | |
| CL2023000426A1 (es) | Neoantígenos ras y usos de los mismos | |
| Church et al. | Transcriptional and functional analyses of neoantigen-specific CD4 T cells during a profound response to anti-PD-L1 in metastatic Merkel cell carcinoma | |
| WO2021262829A3 (en) | Hla class i-restricted t cell receptors against cd20 | |
| BR112013013158B1 (pt) | composições farmacêutica para uso no tratamento de câncer, métodos in vitro para induzir célula apresentadora de antígeno, bem como vetor, e uso | |
| Schmidt et al. | Serological and immunochemical studies of H‐2 allospecificities on K36, a syngeneic tumour of AKR | |
| KR102182555B1 (ko) | T 세포 면역 반응 활성화를 위한 암 치료용 암항원 발굴 플랫폼 | |
| WO2022051449A3 (en) | T cell receptors recognizing r273c or y220c mutations in p53 | |
| IT202000006973A1 (it) | Antigeni herv tumore-specifici e loro uso nella immunoterapia del cancro | |
| EP3447066A1 (en) | New ccl2 peptides for use in cancer therapy | |
| US20240082304A1 (en) | Antigen-specific t cell receptors and chimeric antigen receptors, and methods of use in immune signaling modulation for cancer immunotherapy | |
| US20230197192A1 (en) | Selecting neoantigens for personalized cancer vaccine | |
| De Groot | Immunoinformatic analysis of Chinese Hamster Ovary (CHO) protein contaminants in therapeutic protein formulations |